| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
MGNX Stock Overview
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States.
MacroGenics Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.16 |
| 52 Week High | US$32.81 |
| 52 Week Low | US$3.96 |
| Beta | 2.11 |
| 1 Month Change | -51.68% |
| 3 Month Change | -60.00% |
| 1 Year Change | -85.89% |
| 3 Year Change | -77.77% |
| 5 Year Change | -78.38% |
| Change since IPO | -83.35% |
Recent News & Updates
The Consensus EPS Estimates For MacroGenics, Inc. (NASDAQ:MGNX) Just Fell Dramatically
The analysts covering MacroGenics, Inc. ( NASDAQ:MGNX ) delivered a dose of negativity to shareholders today, by making...
Shareholder Returns
| MGNX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -11.3% | 0.1% | -2.5% |
| 1Y | -85.9% | -21.7% | -10.4% |
Return vs Industry: MGNX underperformed the US Biotechs industry which returned -21.7% over the past year.
Return vs Market: MGNX underperformed the US Market which returned -10.4% over the past year.
Price Volatility
| MGNX volatility | |
|---|---|
| MGNX Average Weekly Movement | 12.8% |
| Biotechs Industry Average Movement | 12.3% |
| Market Average Movement | 7.8% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: MGNX is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.
Volatility Over Time: MGNX's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 427 | Scott Koenig | https://www.macrogenics.com |
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company’s pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies.
MacroGenics Fundamentals Summary
| MGNX fundamental statistics | |
|---|---|
| Market Cap | US$255.15m |
| Earnings (TTM) | -US$217.29m |
| Revenue (TTM) | US$71.67m |
3.6x
P/S Ratio-1.2x
P/E RatioIs MGNX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MGNX income statement (TTM) | |
|---|---|
| Revenue | US$71.67m |
| Cost of Revenue | US$225.58m |
| Gross Profit | -US$153.91m |
| Other Expenses | US$63.38m |
| Earnings | -US$217.29m |
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.54 |
| Gross Margin | -214.76% |
| Net Profit Margin | -303.19% |
| Debt/Equity Ratio | 0% |
How did MGNX perform over the long term?
See historical performance and comparisonValuation
Is MacroGenics undervalued compared to its fair value and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry
1.43x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate MGNX's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate MGNX's fair value for valuation analysis.
Price To Earnings Ratio
PE vs Industry: MGNX is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: MGNX is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate MGNX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: MGNX's PB Ratio (1.4x) is in line with the US Biotechs industry average.
Future Growth
How is MacroGenics forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?
Future Growth Score
1/6Future Growth Score 1/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
5.5%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MGNX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: MGNX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: MGNX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: MGNX's revenue (16.1% per year) is forecast to grow faster than the US market (8% per year).
High Growth Revenue: MGNX's revenue (16.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: MGNX is forecast to be unprofitable in 3 years.
Past Performance
How has MacroGenics performed over the past 5 years?
Past Performance Score
0/6Past Performance Score 0/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
-17.1%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MGNX is currently unprofitable.
Growing Profit Margin: MGNX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: MGNX is unprofitable, and losses have increased over the past 5 years at a rate of 17.1% per year.
Accelerating Growth: Unable to compare MGNX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MGNX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).
Return on Equity
High ROE: MGNX has a negative Return on Equity (-121.92%), as it is currently unprofitable.
Financial Health
How is MacroGenics's financial position?
Financial Health Score
5/6Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: MGNX's short term assets ($218.2M) exceed its short term liabilities ($67.1M).
Long Term Liabilities: MGNX's short term assets ($218.2M) exceed its long term liabilities ($26.1M).
Debt to Equity History and Analysis
Debt Level: MGNX is debt free.
Reducing Debt: MGNX has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MGNX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: MGNX has less than a year of cash runway if free cash flow continues to reduce at historical rates of 13.6% each year
Dividend
What is MacroGenics's current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MGNX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MGNX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MGNX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MGNX's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as MGNX has not reported any payouts.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
5.3yrs
Average management tenure
CEO
Scott Koenig (69 yo)
20.67yrs
Tenure
US$4,868,514
Compensation
Dr. Scott Koenig, M.D., Ph D., has been the President and Chief Executive Officer of Macrogenics, Inc. since September 2001. Dr. Koenig is Co-Founder of Macrogenics.He served as Senior Vice President of R...
CEO Compensation Analysis
Compensation vs Market: Scott's total compensation ($USD4.87M) is above average for companies of similar size in the US market ($USD1.69M).
Compensation vs Earnings: Scott's compensation has increased whilst the company is unprofitable.
Leadership Team
Experienced Management: MGNX's management team is seasoned and experienced (5.3 years average tenure).
Board Members
Experienced Board: MGNX's board of directors are considered experienced (7 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.2%.
Top Shareholders
Company Information
MacroGenics, Inc.'s employee growth, exchange listings and data sources
Key Information
- Name: MacroGenics, Inc.
- Ticker: MGNX
- Exchange: NasdaqGS
- Founded: 2000
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$255.147m
- Shares outstanding: 61.33m
- Website: https://www.macrogenics.com
Number of Employees
Location
- MacroGenics, Inc.
- 9704 Medical Center Drive
- Rockville
- Maryland
- 20850
- United States
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/05/15 00:00 |
| End of Day Share Price | 2022/05/13 00:00 |
| Earnings | 2022/03/31 |
| Annual Earnings | 2021/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.